Rapid Identification and Optimization of Novel Drug Candidates using CLIMB(TM)
DUBLIN, Calif., Jan. 26 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that its Chief Science Officer, Dr. David Bearss, will participate in the symposium, "Accelerating Drug Development with Innovative Discovery Platforms." The event will take place on Tuesday, January 27, 2009 from 1:00 p.m. to 5:15 p.m. EST at the New York Academy of Sciences (NYAS), located at 7 World Trade Center, New York, NY.
Dr. Bearss joined SuperGen in 2006, as a result of the Company's acquisition of Montigen Pharmaceuticals, Inc. Dr. Bearss drives SuperGen's scientific innovation and has enabled the discovery of the kinase inhibitors MP-470, MP-529, SGI-1776 and SGI-1252. He is a recognized expert in targeted small-molecule drug development and the use of genetic model systems for drug discovery and evaluation. Dr. Bearss holds a B.S. from Brigham Young University and a Ph.D. in Cell and Molecular Biology from the University of Texas Health Science Center at San Antonio.
Dr. Bearss' presentation at the NYAS will describe the "Rapid Identification and Optimization of Novel Drug Candidates using CLIMB(TM)," a computationally-driven drug discovery process. CLIMB(TM) identifies new drug leads more efficiently than high-throughput screening, and finds leads with better potential drug-like properties. By screening computationally selected compounds, SuperGen has successfully found inhibitors of PIM-1 and JAK2 protein targets.
The conference is open to the public. For more information, please visit www.nyas.org/events.
About The New York Academy of Sciences
Founded in 1817, the New York Academy of Sciences is an independent, nonprofit organization with 26,000 members in 140 countries. The Society's mission is to advance scientific knowledge, positively impact the major global challenges of society with solutions that are science-based, and increase the number of scientifically informed individuals in society at large.
Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.
This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, our ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.
Contacts Timothy L. Enns SuperGen, Inc. SVP, Corporate Communications & Business Development Tel: (925) 560-2810 E-mail: email@example.com Susanna Chau SuperGen, Inc. Investor Relations Manager Tel: (925) 560-2845 E-mail: firstname.lastname@example.org
SOURCE SuperGen, Inc.